Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models
Wilma A. Stolk, Joaquín M. Prada, Morgan E. Smith, et al.
Clinical Infectious Diseases (2018) Vol. 66, Iss. Supplement_4, pp. S260-S266
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Predicted Impact of COVID-19 on Neglected Tropical Disease Programs and the Opportunity for Innovation
Jaspreet Toor, Emily R. Adams, Maryam Aliee, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 8, pp. 1463-1466
Open Access | Times Cited: 92
Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
Catherine M. Bjerum, Allassane Ouattara, Aboulaye Meïté, et al.
Clinical Infectious Diseases (2019) Vol. 71, Iss. 7, pp. e68-e75
Open Access | Times Cited: 49
The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling

Gates Open Research (2019) Vol. 3, pp. 1538-1538
Open Access | Times Cited: 37
An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
P Jambulingam, Vijesh Sreedhar Kuttiatt, K. Krishnamoorthy, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 2, pp. e0009069-e0009069
Open Access | Times Cited: 31
Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study
Anna Borlase, Epke A. Le Rutte, Soledad Castaño, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 11, pp. e1600-e1611
Open Access | Times Cited: 21
How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Klodeta Kura, Wilma A. Stolk, María‐Gloria Basáñez, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. Supplement_2, pp. S93-S100
Open Access | Times Cited: 4
Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti
Mary Chriselda Antony Oliver, Matthew Graham, Katherine Gass, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. Supplement_2, pp. S160-S168
Open Access | Times Cited: 4
Microplanning improves stakeholders’ perceived capacity and engagement to implement lymphatic filariasis mass drug administration
Caitlin M. Worrell, Tara A. Brant, Alain Javel, et al.
PLoS neglected tropical diseases (2025) Vol. 19, Iss. 3, pp. e0012105-e0012105
Open Access
Counting Down the 2020 Goals for 9 Neglected Tropical Diseases: What Have We Learned From Quantitative Analysis and Transmission Modeling?
T. Déirdre Hollingsworth
Clinical Infectious Diseases (2018) Vol. 66, Iss. suppl_4, pp. S237-S244
Open Access | Times Cited: 32
Elimination of lymphatic filariasis in South East Asia
Sabine Specht, Takeshi Suma, Belén Pedrique, et al.
BMJ (2019), pp. k5198-k5198
Open Access | Times Cited: 29
Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies
Joaquín M. Prada, Wilma A. Stolk, Emma L. Davis, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2021) Vol. 115, Iss. 3, pp. 261-268
Open Access | Times Cited: 23
Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside
Marc P. Hübner, Simon Townson, Suzanne Gokool, et al.
International Journal for Parasitology Drugs and Drug Resistance (2021) Vol. 17, pp. 27-35
Open Access | Times Cited: 22
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold
Joaquín M. Prada, Emma L. Davis, Panayiota Touloupou, et al.
The Journal of Infectious Diseases (2019) Vol. 221, Iss. Supplement_5, pp. S503-S509
Open Access | Times Cited: 24
How should Indonesia consider its neglected tropical diseases in the COVID-19 era? Hopes and challenges (Review)
Shifa Fauziyah, Serius Miliyani Dwi Putri, Zukhaila Salma, et al.
Biomedical Reports (2021) Vol. 14, Iss. 6
Open Access | Times Cited: 19
Heterogeneity in elimination efforts could increase the risk of resurgence of lymphatic filariasis in Madagascar
Elinambinina Rajaonarifara, Benjamín Roche, Cédric B. Chesnais, et al.
Infection Genetics and Evolution (2024) Vol. 120, pp. 105589-105589
Open Access | Times Cited: 2
Subnational Projections of Lymphatic Filariasis Elimination Targets in Ethiopia to Support National Level Policy
Joaquín M. Prada, Panayiota Touloupou, Biruck Kebede, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. Supplement_2, pp. S117-S125
Open Access | Times Cited: 2
An Ensemble Framework for Projecting the Impact of Lymphatic Filariasis Interventions Across Sub-Saharan Africa at a Fine Spatial Scale
Panayiota Touloupou, Claudio Fronterrè, Jorge Cano, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. Supplement_2, pp. S108-S116
Open Access | Times Cited: 2
Distinguishing recrudescence from reinfection in lymphatic filariasis
Young‐Jun Choi, Kerstin Fischer, Aboulaye Meïté, et al.
EBioMedicine (2024) Vol. 105, pp. 105188-105188
Open Access | Times Cited: 2
Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia
Obiora A. Eneanya, Lincoln Gankpala, Charles W. Goss, et al.
American Journal of Tropical Medicine and Hygiene (2021) Vol. 106, Iss. 2, pp. 700-709
Open Access | Times Cited: 13
Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa
Callum Shaw, Angus McLure, Patricia M. Graves, et al.
PLoS neglected tropical diseases (2023) Vol. 17, Iss. 5, pp. e0011347-e0011347
Open Access | Times Cited: 5
Statistical methods for linking geostatistical maps and transmission models: Application to lymphatic filariasis in East Africa
Panayiota Touloupou, Renata Retkutė, T. Déirdre Hollingsworth, et al.
Spatial and Spatio-temporal Epidemiology (2020) Vol. 41, pp. 100391-100391
Open Access | Times Cited: 14
How modelling can help steer the course set by the World Health Organization 2021-2030 roadmap on neglected tropical diseases
Jessica Clark, Wilma A. Stolk, María‐Gloria Basáñez, et al.
Gates Open Research (2021) Vol. 5, pp. 112-112
Open Access | Times Cited: 10
The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages
Anneke S. de Vos, Wilma A. Stolk, Luc E. Coffeng, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 5, pp. e0009011-e0009011
Open Access | Times Cited: 9
Diethylcarbamazine elicits Ca 2+ signals through TRP-2 channels that are potentiated by emodepside in Brugia malayi muscles
Paul Williams, Sudhanva S. Kashyap, Alan P. Robertson, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 10
Open Access | Times Cited: 3
Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021
Molly Brady, Emily Toubali, Margaret Baker, et al.
International Health (2023) Vol. 16, Iss. 5, pp. 479-486
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top